Related Experiment Video
Updated: Sep 19, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Recent Advances in Ablative Therapies for HCC
Arun Gupta1, Raghav Seth1, Ajit Yadav1
1Department of Interventional Radiology, Sir Ganga Ram Hospital, New Delhi, India.
Abstract:
Hepatocellular carcinoma (HCC) is the sixth most common cause of cancer worldwide and ranks third in terms of cancer related mortality. The management options for earlystage HCC include surgical resection, liver transplantation and percutaneous imageguided ablation. However, majority of the patients are not appropriate candidates for liver transplantation or surgical resection. Thus, image-guided tumour ablation has evolved as an accepted curative management option for these patients, according to most of the HCC management guidelines, due to its less invasive nature and proven efficacy. The aim of this article is to review the currently available data and the latest techniques for percutaneous ablation of HCC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

